Author response to Letter to the Editor: ‘Chronological change in alpha‐foetoprotein levels in hepatocellular carcinoma after eradication of hepatitis C virus’

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/156500/2/liv14612.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/156500/1/liv14612_am.pd

Moving toward personalizing MELD exceptions in liver transplantation for hepatocellular carcinoma

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/150509/1/ajt15389_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/150509/2/ajt15389.pd

Frailty, Psychoactive Medications, and Cognitive Dysfunction Are Associated With Poor Patient‐Reported Outcomes in Cirrhosis

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/148384/1/hep30336-sup-0001-Supinfo.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/148384/2/hep30336_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/148384/3/hep30336.pd

Hepatocellular carcinoma surveillance, early detection and survival in a privately insured US cohort

Background/AimsSemiannual hepatocellular carcinoma (HCC) surveillance is recommended in patients with cirrhosis; however, recent studies have raised questions over its utility. We investigated the impact of surveillance on early detection and survival in a nationally representative database.MethodsWe included patients with cirrhosis and HCC from the Optum database (2001‐2015) with >6 months of follow‐up between cirrhosis and HCC diagnoses. Surveillance adherence was defined as proportion of time covered (PTC), with each 6‐month period after abdominal imaging defined as ‘covered’. To determine the association between surveillance and mortality, we compared PTC between fatal and non‐fatal HCC.ResultsOf 1001 patients with cirrhosis and HCC, 256 died with median follow‐up 30 months. Median PTC by any imaging was greater in early‐stage vs late‐stage HCC (43.6% vs 37.4%, P = .003) and non‐fatal vs fatal HCC (40.8% vs 34.3%, P = .001). In multivariable analyses, each 10% increase in PTC was associated with increased early HCC detection (OR 1.07, 95% CI 1.01‐1.12) and decreased mortality (HR 0.95; 95% CI 0.90‐1.00). On subgroup analysis, PTC by CT/MRI was associated with early tumour detection and decreased mortality; however, PTC by ultrasound was only associated with early detection but not decreased mortality. These findings were robust across sensitivity analyses.ConclusionsIn a US cohort of privately insured HCC patients, PTC by any imaging modality was associated with increased early detection and decreased mortality. Continued evaluation of HCC surveillance strategies and effectiveness is warranted.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/154974/1/liv14379_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/154974/2/liv14379.pd

Reply

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/137766/1/hep29248.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/137766/2/hep29248_am.pd

Frequency and Outcomes of Abnormal Imaging in Patients With Cirrhosis Enrolled in a Hepatocellular Carcinoma Surveillance Program

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/148235/1/lt25398_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/148235/2/lt25398.pd

The Quality and Outcomes of Care Provided to Patients with Cirrhosis by Advanced Practice Providers

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/153696/1/hep30695.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/153696/2/hep30695_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/153696/3/hep30695-sup-0001-TableS1-S6.pd

Survival and cost‐effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER–Medicare database

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/135309/1/hep28881-sup-0001-suppinfo.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/135309/2/hep28881_am.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/135309/3/hep28881.pd

A risk score to predict the development of hepatic encephalopathy in a populationâ based cohort of patients with cirrhosis

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/146442/1/hep29628_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/146442/2/hep29628-sup-0001-suppinfo.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/146442/3/hep29628.pd

Reply

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/138269/1/hep29286.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/138269/2/hep29286_am.pd